CLEVELAND, June 25, 2013 -- DATATRAK International, Inc. (OTCQX: DTRK), a leader in developing cloud-based, unified eClinical® technologies and delivering related services for the clinical trials industry, today announced MMS Holdings Inc. is now a DATATRAK Connect™ Partner. MMS Holdings Inc. is a specialty Contract Research Organization (CRO) who focuses on regulatory submission support for the pharmaceutical, biotech and medical device industries.
Known for their strong industry experience and scientific approach to drug development, MMS Holdings Inc. supports all of the top 10 big pharma as well as multiple smaller companies across its spectrum of services - Data Management, Biostatistics, Clinical Programming, Medical and Regulatory Writing, Pharmacovigilance, Clinical Trial Disclosure and Oncology Data Abstraction.
"This partnership will offer our clients a technology solution to more efficiently design, deliver and manage their clinical trials," said Kelly J. Hill, Director of Project and Account Management at MMS Holdings Inc. "Our clients select MMS because of the reliability of our teams and the high quality of our services. We look forward to building on these strengths through this collaboration."
"MMS's focus on regulatory submission support brings a unique addition to the DATATRAK Connect™ Partner Program," stated Laurence P. Birch, DATATRAK's Chairman of the Board and CEO. "We welcome them as a new partner and look forward to furthering their commitment to quality and excellence through the use of the DATATRAK ONE™ solution."
The DATATRAK Connect™ Partner Program is collaboration between synergic companies to accelerate the drug development process. The program allows for extended service offerings to cover all areas of the drug development process with the goal of reducing study costs and furthering business development objectives.
Join DATATRAK Thought Leaders:
Tweet: DATATRAK Signs Niche CRO Partner, MMS Holdings Inc. http://bit.ly/10hmPjN
About MMS Holdings Inc.
MMS Holdings Inc. is a clinical research organization that focuses on regulatory submission support for the pharmaceutical, biotech and medical device industries. Our strong industry experience and scientific approach to drug development makes us a valuable partner in creating compelling submissions that meet rigorous regulatory standards. Our clients span from top 10 pharma to virtual biotech's, and we support each one with the same standard of excellence. Our core service areas include Data Management, Biostatistics, Clinical Programming, Medical and Regulatory Writing, Pharmacovigilance, Clinical Trial Disclosure and Oncology Data Abstraction. Commitment to quality deliverables sets MMS apart from traditional service providers. MMS is the only CRO to be ISO 9001 certified for all services since inception and we maintain detailed quality metrics for every project. For more information visit: http://www.mmsholdings.com.
DATATRAK International is a worldwide technology and services company delivering unified eClinical® solutions and related services for the clinical trials industry. DATATRAK built its multi-component, comprehensive solution on a single, unified platform and expanded this concept to include services delivery via DATATRAK's Clinical and Consulting Services group. The Company delivers a complete portfolio of software products designed to accelerate the reporting of clinical research data from sites to sponsors and ultimately regulatory authorities, faster and more efficiently than loosely integrated technologies. TheDATATRAK ONE™ software solution, deployed worldwide through an ASP or Enterprise Transfer offering, supports Phase I – Phase IV drug and device studies in multiple languages throughout the world. DATATRAK has offices located in Cleveland, Ohio; Bryan, Texas; and Cary (RTP), North Carolina. For more information, visit http://www.datatrak.net.
Except for the historical information contained in this press release, the statements made in this release are forward-looking statements. These forward-looking statements are made based on management's expectations, assumptions, estimates and current beliefs concerning the operations, future results and prospects of the Company and are subject to uncertainties and factors which are difficult to predict and, in many instances, are beyond the control of the Company, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. For a list of certain factors that may cause actual results to differ materially from those contemplated in these forward looking statements, please see the Company's report filed with the OTCQX Market on May 15, 2013 announcing its results for the first quarter of 2013. The Company undertakes no obligation to update publicly or revise any forward-looking statement whether as a result of new information, future events or otherwise.